Repository logo
 

Dynamics in Circulating Proinflammatory Biomarkers for Prognostic Assessment of Patients With Advanced HCC – A Substudy From the SORAMIC Trial

Published version
Peer-reviewed

Change log

Authors

Schütte, Kerstin 
Kupčinskas, Juozas 
Morkunas, Egidijus 
Öcal, Osman 
Schinner, Regina 

Abstract

jats:secjats:titleIntroduction</jats:title>jats:pPrediction of response to treatment in patients with advanced hepatocellular carcinoma (HCC) may assist in the selection of personalized management.</jats:p></jats:sec>jats:secjats:titleObjective</jats:title>jats:pThis exploratory analysis of the palliative arm of the SORAMIC trial (ClinicalTrials.gov NCT01126645) evaluated the prognostic potential of basal and dynamic changes in systemic levels of interleukin 6 (IL-6), interleukin 8 (IL-8), systemic vascular endothelial growth factor (VEGF), and lipopolysaccharide (LPS).</jats:p></jats:sec>jats:secjats:titleMethods</jats:title>jats:pWe evaluated the correlations between overall survival (OS) and concentrations of IL-6, IL-8, VEGF, and LPS at follow-up approximately 7-9 weeks after treatment initialization (FU) compared to baseline (BL) in 90 patients treated either with jats:sup90</jats:sup>Yttrium (jats:sup90</jats:sup>Y) microspheres combined with sorafenib (n = 44) or with sorafenib (n = 46) alone.</jats:p></jats:sec>jats:secjats:titleResults</jats:title>jats:pChanges in IL-6 concentration during treatment showed correlations with the outcome. An increase in IL-6 concentration of less than 16.8 pg/mL over baseline readings was associated with better survival [median OS 16.3 months compared with 8.9 months (p = 0.0354)]. Correlations with survival were not observed for VEGF or LPS concentrations at baseline, at FU, or changes between these time points.</jats:p></jats:sec>jats:secjats:titleConclusions</jats:title>jats:pChanges in IL 6 serum levels at 7-9 weeks after treatment initialization but not in IL 8, VEGF, or LPS add important information on the outcome of advanced HCC patients treated palliatively within the SORAMIC trial.</jats:p></jats:sec>

Description

Keywords

32 Biomedical and Clinical Sciences, 3211 Oncology and Carcinogenesis, Rare Diseases, Digestive Diseases, Cancer, Clinical Trials and Supportive Activities, Liver Cancer, Liver Disease, Clinical Research

Journal Title

Frontiers in Gastroenterology

Conference Name

Journal ISSN

2813-1169
2813-1169

Volume Title

Publisher

Frontiers Media SA
Sponsorship
National Institute for Health and Care Research (IS-BRC-1215-20014)